False Positive and False Negative Diagnoses of Prostate Cancer at Multi-parametric Prostate MRI in Active Surveillance

Overview

Journal Insights Imaging

Publisher Springer

Specialty Radiology

Date 2015 May 24

PMID 26002487

Citations 30

Authors

Jeffrey S Quon

Bardia Moosavi

Maneesh Khanna

Trevor A Flood

Christopher S Lim

Nicola Schieda

Affiliations

Soon will be listed here.

Abstract

Keypoints: • Multi-parametric MRI plays a critical role in prostate cancer active surveillance. • Low T2W signal intensity structures appear dark on ADC, potentially simulating cancer. • Stromal BPH mimics cancer at DWI and DCE. • Long b value trace EPI should be reviewed • Targeted biopsy of MR-detected lesions using TRUS guidance may be challenging.

Citing Articles

Systematic Review of AI-Assisted MRI in Prostate Cancer Diagnosis: Enhancing Accuracy Through Second Opinion Tools.

Alqahtani S Diagnostics (Basel). 2024; 14(22).

PMID: 39594242 PMC: 11592433. DOI: 10.3390/diagnostics14222576.

Diffusion kurtosis imaging and standard diffusion imaging in the magnetic resonance imaging assessment of prostate cancer.

Palumbo P, Martinese A, Antenucci M, Granata V, Fusco R, De Muzio F Gland Surg. 2024; 12(12):1806-1822.

PMID: 38229839 PMC: 10788566. DOI: 10.21037/gs-23-53.

Dynamic Contrast-Enhanced Study in the mpMRI of the Prostate-Unnecessary or Underutilised? A Narrative Review.

Guljas S, Dupan Krivdic Z, Dreznjak Madunic M, Sambic Penc M, Pavlovic O, Krajina V Diagnostics (Basel). 2023; 13(22).

PMID: 37998624 PMC: 10670922. DOI: 10.3390/diagnostics13223488.

Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.

Rafikova G, Gilyazova I, Enikeeva K, Pavlov V, Kzhyshkowska J Int J Mol Sci. 2023; 24(16).

PMID: 37628978 PMC: 10454494. DOI: 10.3390/ijms241612797.

Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms.

Yu X, Liu R, Song L, Gao W, Wang X, Zhang Y Front Oncol. 2023; 13:1165732.

PMID: 37456243 PMC: 10348634. DOI: 10.3389/fonc.2023.1165732.

References

Quon J, Kielar A, Jain R, Schieda N . Assessing the utilization of functional imaging in multiparametric prostate MRI in routine clinical practice. Clin Radiol. 2015; 70(4):373-8. DOI: 10.1016/j.crad.2014.12.001. View

Isebaert S, De Keyzer F, Haustermans K, Lerut E, Roskams T, Roebben I . Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. Eur J Radiol. 2011; 81(3):e217-22. DOI: 10.1016/j.ejrad.2011.01.107. View

Bouye S, Potiron E, Puech P, Leroy X, Lemaitre L, Villers A . Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. Prostate. 2008; 69(1):105-13. DOI: 10.1002/pros.20859. View

Hegde J, Mulkern R, Panych L, Fennessy F, Fedorov A, Maier S . Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging. 2013; 37(5):1035-54. PMC: 3741996. DOI: 10.1002/jmri.23860. View

Bonekamp D, Jacobs M, El-Khouli R, Stoianovici D, Macura K . Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics. 2011; 31(3):677-703. PMC: 3093638. DOI: 10.1148/rg.313105139. View

Rosenkrantz A, Triolo M, Melamed J, Rusinek H, Taneja S, Deng F . Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging. 2014; 41(3):708-14. PMC: 4696491. DOI: 10.1002/jmri.24598. View

Froehlich J, Metens T, Chilla B, Hauser N, Klarhoefer M, Kubik-Huch R . Should less motion sensitive T2-weighted BLADE TSE replace Cartesian TSE for female pelvic MRI?. Insights Imaging. 2012; 3(6):611-8. PMC: 3505563. DOI: 10.1007/s13244-012-0193-9. View

Barentsz J, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G . ESUR prostate MR guidelines 2012. Eur Radiol. 2012; 22(4):746-57. PMC: 3297750. DOI: 10.1007/s00330-011-2377-y. View

Thomsen F, Brasso K, Klotz L, Roder M, Berg K, Iversen P . Active surveillance for clinically localized prostate cancer--a systematic review. J Surg Oncol. 2014; 109(8):830-5. DOI: 10.1002/jso.23584. View

10.

Amin A, Epstein J . Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma. Am J Surg Pathol. 2011; 35(4):615-9. PMC: 4425125. DOI: 10.1097/PAS.0b013e31820eb25b. View

11.

Nagel K, Schouten M, Hambrock T, Litjens G, Hoeks C, Ten Haken B . Differentiation of prostatitis and prostate cancer by using diffusion-weighted MR imaging and MR-guided biopsy at 3 T. Radiology. 2013; 267(1):164-72. DOI: 10.1148/radiol.12111683. View

12.

Wang X, Qian Y, Liu B, Cao L, Fan Y, Zhang J . High-b-value diffusion-weighted MRI for the detection of prostate cancer at 3 T. Clin Radiol. 2014; 69(11):1165-70. DOI: 10.1016/j.crad.2014.07.013. View

13.

Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V . EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2010; 59(1):61-71. DOI: 10.1016/j.eururo.2010.10.039. View

14.

Metens T, Miranda D, Absil J, Matos C . What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T?. Eur Radiol. 2011; 22(3):703-9. DOI: 10.1007/s00330-011-2298-9. View

15.

Claus F, Hricak H, Hattery R . Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics. 2004; 24 Suppl 1:S167-80. DOI: 10.1148/24si045516. View

16.

Vargas H, Akin O, Franiel T, Goldman D, Udo K, Touijer K . Normal central zone of the prostate and central zone involvement by prostate cancer: clinical and MR imaging implications. Radiology. 2012; 262(3):894-902. PMC: 3285222. DOI: 10.1148/radiol.11110663. View

17.

Akin O, Sala E, Moskowitz C, Kuroiwa K, Ishill N, Pucar D . Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006; 239(3):784-92. DOI: 10.1148/radiol.2392050949. View

18.

Hoeks C, Barentsz J, Hambrock T, Yakar D, Somford D, Heijmink S . Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011; 261(1):46-66. DOI: 10.1148/radiol.11091822. View

19.

Watanabe Y, Nagayama M, Araki T, Terai A, Okumura A, Amoh Y . Targeted biopsy based on ADC map in the detection and localization of prostate cancer: a feasibility study. J Magn Reson Imaging. 2012; 37(5):1168-77. PMC: 3664425. DOI: 10.1002/jmri.23908. View

20.

Rosenkrantz A, Kopec M, Kong X, Melamed J, Dakwar G, Babb J . Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging. J Magn Reson Imaging. 2010; 31(6):1387-94. DOI: 10.1002/jmri.22172. View